Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis : A single-center retrospective study
Copyright © 2016 Elsevier Ltd. All rights reserved..
OBJECTIVE: We compared the efficacy and clinical outcomes of vindesine and prednisone (VP) and cyclophosphamide, etoposide, vindesine, and prednisone (CEVP) regimens as first-line treatment for multisystem (MS) or multifocal single system (SS-m) adult Langerhans cell histiocytosis (LCH).
METHOD: Clinical features, treatment response, and survival of adults with Langerhans cell histiocytosis treated at our center from January 2001 to January 2015 were reviewed retrospectively.
RESULTS: Forty-five adult MS or SS-m LCH patients were treated (N=31, CEVP group; N=14, VP group). Both treatment groups had similar gender distributions, patient ages, and extent of disease. The non-active disease rate for both groups was 70.0% and 64.3% (P=0.775), respectively. Median follow-up was 74.9 (range: 2.8-183.6) months and recurrence rates were 71.0% and 78.6% (P=0.593), respectively. The need for second-line therapy was 64.5% and 71.4% (P=0.649), respectively, and mortality rates were 9.7% and 15.4% (P=0.586), respectively. Neutropenia occurred in 48.4% of CEVP-treated patients and 7.1% of VP-treated patients (P=0.008).
CONCLUSIONS: CEVP or VP regimens for the treatment of adult SS-m or MS LCH showed similar efficacies, and both regimens were associated with high disease recurrence and the need for second-line therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Leukemia research - 42(2016) vom: 26. März, Seite 43-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Duan, M-H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6PLQ3CP4P3 |
|---|
| Anmerkungen: |
Date Completed 25.07.2016 Date Revised 05.03.2016 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.leukres.2016.01.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM257311998 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM257311998 | ||
| 003 | DE-627 | ||
| 005 | 20231224182542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.leukres.2016.01.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0857.xml |
| 035 | |a (DE-627)NLM257311998 | ||
| 035 | |a (NLM)26859782 | ||
| 035 | |a (PII)S0145-2126(16)30012-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Duan, M-H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis |b A single-center retrospective study |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.07.2016 | ||
| 500 | |a Date Revised 05.03.2016 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVE: We compared the efficacy and clinical outcomes of vindesine and prednisone (VP) and cyclophosphamide, etoposide, vindesine, and prednisone (CEVP) regimens as first-line treatment for multisystem (MS) or multifocal single system (SS-m) adult Langerhans cell histiocytosis (LCH) | ||
| 520 | |a METHOD: Clinical features, treatment response, and survival of adults with Langerhans cell histiocytosis treated at our center from January 2001 to January 2015 were reviewed retrospectively | ||
| 520 | |a RESULTS: Forty-five adult MS or SS-m LCH patients were treated (N=31, CEVP group; N=14, VP group). Both treatment groups had similar gender distributions, patient ages, and extent of disease. The non-active disease rate for both groups was 70.0% and 64.3% (P=0.775), respectively. Median follow-up was 74.9 (range: 2.8-183.6) months and recurrence rates were 71.0% and 78.6% (P=0.593), respectively. The need for second-line therapy was 64.5% and 71.4% (P=0.649), respectively, and mortality rates were 9.7% and 15.4% (P=0.586), respectively. Neutropenia occurred in 48.4% of CEVP-treated patients and 7.1% of VP-treated patients (P=0.008) | ||
| 520 | |a CONCLUSIONS: CEVP or VP regimens for the treatment of adult SS-m or MS LCH showed similar efficacies, and both regimens were associated with high disease recurrence and the need for second-line therapy | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Histiocytosis | |
| 650 | 4 | |a Langerhans-cell histiocytosis | |
| 650 | 4 | |a Multisystem | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Vindesine |2 NLM | |
| 650 | 7 | |a RSA8KO39WH |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Han, X |e verfasserin |4 aut | |
| 700 | 1 | |a Li, J |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, W |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, T-N |e verfasserin |4 aut | |
| 700 | 1 | |a Han, B |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuang, J-L |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, S-J |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, X-X |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, H-C |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, M |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, C |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, D-B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia research |d 1991 |g 42(2016) vom: 26. März, Seite 43-6 |w (DE-627)NLM000939560 |x 1873-5835 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2016 |g day:26 |g month:03 |g pages:43-6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.leukres.2016.01.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2016 |b 26 |c 03 |h 43-6 | ||